Open AccessA recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
Author(s) -
Stephanie L. Foster,
Courtney Woolsey,
Viktoriya Borisevich,
Krystle N. Agans,
Abhishek N. Prasad,
Daniel J. Deer,
Joan B. Geisbert,
Natalie S. Dobias,
Karla A. Fenton,
Robert W. Cross,
Thomas W. Geisbert
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2200065119
Subject(s) - virology , vesicular stomatitis virus , vaccination , virus , vesicular stomatitis , outbreak , recombinant dna , biology , mononegavirales , vector (molecular biology) , vesicular stomatitis indiana virus , viral shedding , paramyxoviridae , viral disease , biochemistry , gene
Significance Concern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.